Theyre often a sign your body is adjusting and may require small changes in nutrition, activity, or dosing
At the end of 40 or 42 weeks (study time varied by trial), urine albumin-to-creatinine ratio (UACR) was significantly reduced among participants assigned to tirzepatide 5, 10, or 15 mg as compared with those assigned to all pooled comparators (placebo, semaglutide, insulin degludec, and insulin glargine) with adjusted mean percent changes of 19.3% [95% CI 12.525.5%], 22.0% [95% CI 15.328.1%], and 26.3% [95% CI 20.032.0%], respectively, with a greater reduction observed in participants with a UACR 30 mg/g at baseline [96]
MeAgain is built GLP-1-first, so your dose, injection site, food, protein, fiber, water, side effects, weight, progress photos and medication context live together
Electrospinning and electrospraying technologies for food applications